Duration of trastuzumab for HER2-positive breast cancer

Title
Duration of trastuzumab for HER2-positive breast cancer
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 14, Issue 8, Pages 678-679
Publisher
Elsevier BV
Online
2013-06-11
DOI
10.1016/s1470-2045(13)70273-0

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started